Trilaciclib is a promising drug candidate that has shown potential in treating various types of cancer. However, during the manufacturing process of Trilaciclib, some impurities may be generated that could potentially affect the safety and efficacy of the drug. These impurities need to be identified, characterized, and controlled to ensure that Trilaciclib meets the required quality standards for clinical use. The identification and control of Trilaciclib impurities are critical for ensuring patient safety and the success of clinical trials.
